Last reviewed · How we verify

critical care patients venofer

Assistance Publique - Hôpitaux de Paris · Phase 1 active Small molecule

critical care patients venofer is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 1 development. Also known as: iron (ferric hydroxide sucrose) injection.

At a glance

Generic namecritical care patients venofer
Also known asiron (ferric hydroxide sucrose) injection
SponsorAssistance Publique - Hôpitaux de Paris
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about critical care patients venofer

What is critical care patients venofer?

critical care patients venofer is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris.

Who makes critical care patients venofer?

critical care patients venofer is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

Is critical care patients venofer also known as anything else?

critical care patients venofer is also known as iron (ferric hydroxide sucrose) injection.

What development phase is critical care patients venofer in?

critical care patients venofer is in Phase 1.

Related